AMGEN INC | 55,04 Euro | +0,280 +0,51 % | |
| WKN: 867900 ISIN: US0311621009 Ticker-Symbol: AMG | Frankfurt | 25.05.12 | 18:26 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ-100S&P 100 S&P 500 NASDAQ Biotech |
|
| |||||||||||||||
| |||||||||||||||||
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 26.05. | Amgen has the Highest Level of Cash in the Biotechnology Industry | 1 | SmarTrend | |
| 23.05. | Amgen Announces Voting Results Of Stockholders Meeting; CEO Kevin Sharer Retires | 61 | AFX News | |
| THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced voting results from the
Company's Annual Meeting of Stockholders, held at the Four Seasons Hotel,
Westlake Village, Calif. Approximately... Mehr lesen zu: Amgen Announces Voting Results Of Stockholders Meeting; CEO Kevin Sharer Retires | ||||
| 23.05. | Amgen Announces Voting Results of Annual Meeting of Stockholders | 26 | PR Newswire | |
| THOUSAND OAKS, Calif., May 23, 2012 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held at the Four Seasons Hotel, Westlake Village... Mehr lesen zu: Amgen Announces Voting Results of Annual Meeting of Stockholders | ||||
| 19.05. | /C O R R E C T I O N -- Amgen/ | 158 | PR Newswire | |
| In the news release, Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, issued 16-May-2012... Mehr lesen zu: /C O R R E C T I O N -- Amgen/ | ||||
| 18.05. | After Yesterday's Decline of 1.97%, Amgen Offers Investors Better Value | 7 | SmarTrend | |
| 18.05. | Look for Shares of Amgen to Potentially Rebound after Yesterday's 1.97% Sell Off | 2 | SmarTrend | |
| 18.05. | Amgen Crosses Below its 10-day MA | 1 | SmarTrend | |
| 17.05. | Amgen Presents Oncology Data | 9 | Zacks | |
| 17.05. | Amgen: AMG 103 Phase 2 Data Shows High CR Rate In Leukemia Patients | 68 | AFX News | |
| THOUSAND OAKS (dpa-AFX) - Biotechnology firm Amgen (AMGN) on Wednesday
announced updated results from a Phase 2 study, which showed that treatment with
blinatumomab (AMG 103) helped achieve... Mehr lesen zu: Amgen: AMG 103 Phase 2 Data Shows High CR Rate In Leukemia Patients | ||||
| 17.05. | Amgen Reports Results On Exploratory Biomarker Analysis For AMG 102 Response | 55 | AFX News | |
| THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced results from an exploratory
biomarker analysis evaluating MET expression as a predictor of clinical response
to rilotumumab (AMG 102).The... Mehr lesen zu: Amgen Reports Results On Exploratory Biomarker Analysis For AMG 102 Response | ||||
| 17.05. | Amgen Says BiTE Antibody Blinatumomab Achieved High Rate Of Complete Response | 59 | AFX News | |
| THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) announced updated results from a
Phase 2 study that showed treatment with blinatumomab or AMG 103 helped achieve
a high-rate of complete response... Mehr lesen zu: Amgen Says BiTE Antibody Blinatumomab Achieved High Rate Of Complete Response | ||||
| 17.05. | Amgen (AMGN) Says AMG 103 Achieves High-Rate of CR in B-Precursor ALL Following Phase 2 Data | - | StreetInsider.com | |
| 17.05. | Amgen (AMGN) Updates on Exploratory Biomarker Analysis for AMG 102 Response Predictor | - | StreetInsider.com | |
| 17.05. | Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | 30 | PR Newswire | |
| THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate... Mehr lesen zu: Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | ||||
| 14.05. | XFRA DIVIDEND INFORMATION - 14.05.2012 - 3 | 165 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 14.05.2012 EX DIVIDENDE GEHANDELT.
THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 14.05.2012.
INSTR EXCH ISIN INSTRUMENT NAME DIVIDEND AMOUNT
MPN XFRA US56585A1025... Mehr lesen zu: XFRA DIVIDEND INFORMATION - 14.05.2012 - 3 | ||||
| 14.05. | XETR DIVIDEND INFORMATION - 14.05.2012 - 2 | 411 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 14.05.2012 EX DIVIDENDE GEHANDELT.
THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 14.05.2012.
INSTR EXCH ISIN INSTRUMENT NAME DIVIDEND AMOUNT
PJX XETR US71654V1017... Mehr lesen zu: XETR DIVIDEND INFORMATION - 14.05.2012 - 2 | ||||
| 11.05. | Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars | 49 | AFX News | |
| THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced that Joseph Miletich,
senior vice president of Research and Development at Amgen will testify at the
United States Food and Drug Administration... Mehr lesen zu: Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars | ||||
| 11.05. | Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars | 39 | PR Newswire | |
| THOUSAND OAKS, Calif., May 11, 2012 /PRNewswire/ --Amgen (NASDAQ:AMGN) announced today that Joseph P. Miletich, M.D., Ph.D., senior vice president of Research and Development at Amgen will testify... Mehr lesen zu: Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars | ||||
| 11.05. | XETR DIVIDEND INFORMATION - 14.05.2012 - 1 | 559 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 11.05.2012 CUM DIVIDENDE UND AM 14.05.2012
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 11.05.2012. THE
EX-DIVIDEND DAY WILL BE 14.05.2012.
... Mehr lesen zu: XETR DIVIDEND INFORMATION - 14.05.2012 - 1 | ||||
| 11.05. | XFRA DIVIDEND INFORMATION - 14.05.2012 - 1 | 72 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 11.05.2012 CUM DIVIDENDE UND AM 14.05.2012
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 11.05.2012. THE
EX-DIVIDEND DAY WILL BE 14.05.2012.
... Mehr lesen zu: XFRA DIVIDEND INFORMATION - 14.05.2012 - 1 | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| QIAGEN NV | 13,170 | +0,73 % | Qiagen - Weiteres Rallypotential bis ... |
| BIOGEN IDEC | 105,33 | +0,44 % | Biogen: Kaufen - Ein Aufwärtstrend wie an der Schnur gezogen ! |
| MORPHOSYS AG | 17,365 | -1,22 % | DAX mit Rebound: BMW, BASF, Bayer, Süss Microtec, Morphosys, Solarworld und Commerzbank im Fokus |
| BB BIOTECH AG | 66,40 | +0,96 % | BB Biotech: Wie an der Schnur gezogen |
| AGENNIX AG | 1,720 | +1,18 % | ERS: AGENNIX AG / 3-Monatsbericht 2012 |
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
